Product image of Icatibant Stada (Icatibant) supplied by GNH India

Icatibant Stada

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada (Icatibant)

Icatibant, the active ingredient in Icatibant Stada, is a Bradykinin B2 receptor antagonist presented as a subcutaneous injection solution for subcutaneous use. It treats hereditary angioedema associated with C1‑inhibitor deficiency in patients requiring acute attack management.

GNH India supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Icatibant is used to manage hereditary angioedema, a bradykinin‑mediated disorder.
  • Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during acute attacks, reducing duration and severity of symptoms.

How It Works

  • Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and activating the receptor. This antagonism inhibits bradykinin‑induced vasodilation and increased vascular permeability, thereby limiting the plasma‑extravasation that causes the swelling characteristic of hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin redness.
  • Swelling at injection site: transient edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or pruritus.
  • Anaphylaxis: severe, potentially life‑threatening allergic response.
  • Severe angioedema: swelling of face, lips, or airway.
  • Hypotension: marked drop in blood pressure.
  • Thrombocytopenia: reduced platelet count.
  • Severe injection‑site necrosis: tissue damage at the site.

Precautions & Warnings

  • Before using Icatibant, consider the following safety measures.
  • Pregnancy: consult a healthcare professional; safety data are limited.
  • Breastfeeding: discuss risks and benefits with a physician.
  • Renal impairment: monitor closely as clearance may be affected.
  • Concurrent bradykinin‑modulating therapy: avoid overlapping treatments.
  • Allergy history: assess for prior hypersensitivity to peptide drugs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medications that influence the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema.
  • Neprilysin inhibitors: elevate bradykinin, potentially reducing Icatibant efficacy.
  • Estrogen‑containing therapies: can exacerbate hereditary angioedema attacks.

Moderate Interactions (Monitor Closely)

  • Other B2‑receptor antagonists: additive pharmacodynamic effects.
  • Antihistamines: may mask early signs of hypersensitivity.
  • Corticosteroids: monitor for overlapping immunomodulatory effects.
  • Diuretics: watch for blood pressure fluctuations.
  • NSAIDs: potential for increased vascular permeability.

Frequently Asked Questions

Icatibant Stada is indicated for the acute treatment of hereditary angioedema attacks in patients with C1‑inhibitor deficiency. By blocking the bradykinin B2 receptor, it rapidly reduces swelling and associated discomfort during an episode.

Icatibant is a selective antagonist of the bradykinin B2 receptor. It prevents bradykinin from binding to this receptor, thereby inhibiting the vasodilation and increased vascular permeability that cause the swelling seen in hereditary angioedema.

The dosage regimen for Icatibant Stada is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the attack. Healthcare professionals follow the approved labeling and clinical guidelines when prescribing.

Safety data for Icatibant Stada in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Icatibant is a peptide‑based B2‑receptor antagonist, whereas alternative treatments include C1‑esterase inhibitor concentrates and newer monoclonal antibodies targeting kallikrein or factor XII. Icatibant offers rapid subcutaneous administration and direct blockade of bradykinin, making it useful for patients who prefer self‑injection and need quick symptom relief.

Icatibant Stada should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain product stability.

The medication is supplied as a sterile solution for subcutaneous injection. A single dose is typically injected into the abdominal wall or thigh using a pre‑filled syringe or autoinjector, as instructed by a qualified healthcare professional.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe angioedema affecting the airway, and significant hypotension. Patients should be monitored for signs of allergic response and instructed to seek immediate medical attention if symptoms worsen.

Icatibant Stada is contraindicated in individuals with known hypersensitivity to icatibant or any of the excipients in the formulation. Patients with a history of severe allergic reactions to peptide drugs should avoid its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT